Press Releases

MANHASSET, N.Y., Oct. 17, 2019 /PRNewswire/ -- For the first time, Jacqueline Molin

TOLEDO, Ohio, Oct. 17, 2019 /PRNewswire/ -- Welltower Inc. (NYSE: WELL) today announced that it has been granted Prime status by ISS ESG, one of the world's leading rating agencies for sustainable investments. The ISS ESG rating considers Environmental, Social and Governance ("ESG") practices by evaluating more than 100 industry-specific indicators. Companies that achiev

LOS ANGELES, Oct. 17, 2019 /PRNewswire/ -- Teijin Limited (Teijin) and

PHOENIX, Oct. 17, 2019 /PRNewswire/ -- Harvest Health & Recreation, Inc. (CSE: HARV, OTCQX: HRVSF) ("Harvest"), a vertically integrated cannabis company with one

HOUSTON, Oct. 17, 2019 /PRNewswire/ -- American Society of Pharmacovigilance (ASP) directors today presented to key stakeholders in the field of pharmacogenomics, a detailed framework for building a national, public-private multi-disciplinary stakeholder collaboration to accelerate the development of precision medicine practices as a standard of care. The Standardizing L

PHOENIX, Oct. 17, 2019 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading commercial stage biotechnology company focus

NEW YORK, Oct. 17, 2019 /PRNewswire/ -- New York Times best-selling author Deepak Chopra and philanthropist Alice Walton announced that the Sages and Scientists 2019 Symposium, the pre-eminent convening of global well-being experts and thought leaders of its kind, will b

WASHINGTON, Oct. 17, 2019 /PRNewswire/ -- Wearables may provide helpful health data, but people are concerned that their fitness tracker could give inaccurate medical data, according to

FRANKLIN, Tenn., Oct. 17, 2019 /PRNewswire/ -- Four in ten adults in the U.S. age 65 or older have some form of age-associated memory loss, acc

SAN FRANCISCO, Oct. 17, 2019 /PRNewswire/ -- Amygdala Neurosciences (a private company) announced today the start of dosing in the National Institute on Alcohol Abuse and Alcoholism (NIAAA, an Institute of the National Institutes of Health (NIH)) sponsored Phase 2 proof-of-concept study of ANS-6637 in patients with alcohol use disorder. In the U